Pfizer takes aim at BMS' first-in-class Zeposia with FDA nod for ulcerative colitis drug Velsipity

Bristol Myers Squibb’s Zeposia is no longer the only S1P receptor modulator on the market for ulcerative colitis, thanks to an FDA approval for what appears to be a more effective drug from Pfizer.

The FDA has approved Pfizer’s etrasimod under the brand name Velsipity as an oral, once-daily treatment for adults with moderate to severe active ulcerative colitis, the company said Friday.